Swiss Pharmaceutical Hegemony: Intellectual Property Architecture and Global R&D Dominance Switzerland controls a disproportionate share of global pharmaceutical value. While […]

AbbVie built 311 patent applications around a single rheumatoid arthritis antibody and extracted more than $200 billion in cumulative revenue

Section 1: What Paragraph IV MDL Actually Is (and Why the Stakes Are So High) H2: The Collision of Patent

Quality failures in generic drug manufacturing are not a compliance inconvenience. They are a market-exit event. Between 2022 and 2024,

A comprehensive technical guide for pharma IP teams, R&D leads, and institutional investors on translating patent surveillance into commercial advantage.

The global pharmaceutical industry in 2026 exists in a state of hyper-dynamic transition, defined by the convergence of the most

Pharmaceutical procurement teams spend enormous effort negotiating the price on a purchase order. Then they lose more money in the

Switzerland generates more patent applications per capita than any other country on earth. In 2024, the European Patent Office received

We’re excited to announce that DrugPatentWatch is now available on the Snowflake Marketplace, making it easier than ever for organizations